StockData

Kamada vs Zhengye Biotechnology

KMDA and ZYBT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KMDA and ZYBT compare

Kamada grew revenue faster over the last twelve months (13.2% versus −37.6% for Zhengye Biotechnology).

Kamada scores higher on the StockData Score (5 against 4 for Zhengye Biotechnology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKMDAZYBT
Size and price
Share price$8.11$1.43
Change, 1 year14.5%−33.5%
Change, 5 years28.5%–
Beta (5Y)0.840.41
Employees39351
StockData Score
Total score5 (better)4
Valuation score00
Growth score2 (better)0
Performance score01 (better)
Health score33
Dividend score00
Growth
Revenue growth (TTM)13.2% (better)−37.6%
Revenue growth, 5Y average6.3%–
Net income growth (TTM)–−717%
EPS growth, 5Y average−1.6%–
Profitability
Gross margin40.8% (better)20.5%
Operating margin14.5% (better)−60.6%
Net margin–−60.0%
FCF margin–10.6%
Return on equity–−26.1%
Return on invested capital–−18.1%
Financial health
Debt / equity–0.26
Net debt / EBITDA−0.54–
Interest coverage26.8× (better)−20.7×
Current ratio4.06 (better)1.14
Piotroski F-score–3
Ownership
Held by institutions8.6%–
Held by insiders45.3%90.7%
Insider net buying, 12 months−$1.7M–
Short interest, % of float0.53%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.